On April 4th 2018 The Zuellig Group Incorporated (ZGI), the majority shareholder of Zuellig Pharma, completed the acquisition of the approximately 20% investment in Zuellig Pharma held by a wholly owned subsidiary of Temasek.

The relationship with Temasek has proven beneficial to both parties, and both ZGI and the board of Zuellig Pharma wish to record their appreciation of the contribution of the Temasek directors to the work and deliberations of the board.

The consolidation of ZGI’s interest in Zuellig Pharma recognises the commitment of management to Zuellig Pharma’s strategy and will not result in any changes to management or to Zuellig Pharma’s enduring and exceptional commitment to its customers and clients.